tradmap

TARS Tarsus Pharmaceuticals, Inc.

$63.16 +1.04%

Healthcare · Biological Products, (No Diagnostic Substances)

Tarsus Pharmaceuticals, Inc. (TARS) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $2.7 billion. Shares last traded at $63.16, 25.9% below their 52-week high. Over the past year the stock is up 60.4%. Net profit margin is -14.6%, below the peer median of 6.3%. Revenue grew 146.7% year over year.

Market Cap
$2.7B
Shares Out
43.0M
EPS (TTM)
$-3.31
P/E Ratio
P/S Ratio
6.02
P/B Ratio
7.79
Dividend / Share
Dividend Yield
52-Week High
$85.25
52-Week Low
$38.53
Volume
19,340
Avg Vol (3m)
33,914.778

Performance

1W
+0.80%
1M
+3.15%
3M
-5.36%
6M
-19.19%
YTD
-21.63%
1Y
+60.39%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
54.75
SMA (50)
$63.24
SMA (200)
$68.29
Price vs SMA50
-0.13%
Price vs SMA200
-7.51%
ATR (14)
$2.75

Financials

Revenue
$451M
Net Income
$-66M
Gross Margin
Operating Margin
-15.7%
Net Margin
-14.6%
Return on Equity
-18.9%
Return on Assets
-11.4%
Current Ratio
3.74
Debt / Equity
0.21
Revenue Growth (YoY)
+146.7%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q1 2026 $-0.16 2026-05-06
FY 2025 $-1.59 2026-02-23
Q3 2025 $-1.40 2025-11-04
Q2 2025 $-1.11 2025-08-06
Q1 2026 $-0.64 2026-05-06
FY 2025 $-3.07 2026-02-23

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

TARS vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/S vs peers
6.02 / 5.21 med
+15% premium
Net margin vs peers
-14.6% / 6.3% med
below median
1–14 of 14
AMGNAmgen$182.1B23.624.9621.0%-1.27%
GILDGilead Sciences$153.5B18.045.2128.9%-1.46%
RVMDRevolution Medicines, Inc.$34.6B-30.62+3.14%
BIIBBiogen$29.0B22.442.9313.1%-1.15%
MRNAModerna$25.4B-8.99+3.22%
NBIXNeurocrine Biosciences Inc$15.9B33.245.5616.7%-0.48%
EXELExelixis, Inc.$13.1B16.685.6233.7%-1.04%
KRYSKrystal Biotech, Inc.$10.2B50.0226.3352.6%+1.68%
TECHBio-Techne$9.1B123.617.446.0%+5.36%
HALOHalozyme Therapeutics, Inc.$8.1B25.675.8222.7%-0.03%
IBRXImmunitybio, Inc.$7.7B-21.87+5.01%
RGENRepligen Corp$7.4B152.2710.086.6%-1.20%
KYMRKymera Therapeutics, Inc.$7.4B23.88+0.44%
PCVXVaxcyte, Inc.$7.4B-9688.00+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.